B Group Inc. Buys Shares of 50,651 Assembly Biosciences, Inc. (NASDAQ:ASMB)

B Group Inc. acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 50,651 shares of the biopharmaceutical company's stock, valued at approximately $799,000. Assembly Biosciences comprises approximately 0.5% of B Group Inc.'s investment portfolio, making the stock its 13th biggest holding. B Group Inc. owned about 0.80% of Assembly Biosciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ASMB. JPMorgan Chase & Co. grew its holdings in shares of Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 3,442 shares during the period. Palumbo Wealth Management LLC acquired a new position in Assembly Biosciences during the 4th quarter worth about $180,000. Marshall Wace LLP lifted its position in shares of Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 2,098 shares in the last quarter. Monimus Capital Management LP purchased a new position in Assembly Biosciences in the 4th quarter valued at approximately $664,000. Finally, Peapod Lane Capital LLC purchased a new position in Assembly Biosciences in the fourth quarter valued at $994,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ASMB has been the topic of a number of recent analyst reports. Guggenheim assumed coverage on shares of Assembly Biosciences in a research report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 price objective on the stock. HC Wainwright restated a "neutral" rating on shares of Assembly Biosciences in a research report on Monday, March 24th. Finally, StockNews.com downgraded Assembly Biosciences from a "buy" rating to a "hold" rating in a report on Monday, March 24th.

Assembly Biosciences Stock Up 1.6 %

Shares of ASMB traded up $0.17 during mid-day trading on Friday, reaching $10.70. 9,084 shares of the company's stock were exchanged, compared to its average volume of 25,758. The company has a market cap of $81.73 million, a price-to-earnings ratio of -1.59 and a beta of 0.65. The company has a 50-day simple moving average of $10.65 and a two-hundred day simple moving average of $13.91. Assembly Biosciences, Inc. has a 52-week low of $7.75 and a 52-week high of $19.93.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The firm had revenue of $7.36 million during the quarter, compared to analyst estimates of $7.05 million. As a group, equities research analysts predict that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.